Eric Padron

15.1k citations

331 papers · 4.1k indexed · h-index 31

Impact in

Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Virus-based gene therapy research
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 278
- Acute Myeloid Leukemia Research 260
- Chronic Myeloid Leukemia Treatments 65
Genetics 172
- Myeloproliferative Neoplasms: Diagnosis and Treatment 120
- Chronic Lymphocytic Leukemia Research 53

Co-authors: Rami S. Komrokji (251 shared papers)Alan F. List (156 shared papers)Jeffrey E. Lancet (208 shared papers)David A. Sallman (172 shared papers)Najla Al Ali (91 shared papers)Najla H. Al Ali (59 shared papers)Robert McKenna (6 shared papers)Mavis Agbandje‐McKenna (6 shared papers)
Journals: Blood (156 papers)Leukemia Research (15 papers)Leukemia (13 papers)American Journal of Hematology (9 papers)Journal of Clinical Oncology (6 papers)
Partner nations: United States France Italy

In The Last Decade

Eric Padron

296 papers receiving 4.1k citations

Peers

Countries citing papers authored by Eric Padron

Since Specialization

Citations

This map shows the geographic impact of Eric Padron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Padron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Padron more than expected).

Fields of papers citing papers by Eric Padron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Padron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Padron. The network helps show where Eric Padron may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Padron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Padron Line = papers co-authored together Eric Padron links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 331 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype Blood ·Ashley A. Basiorka, Kathy L. McGraw, Erika A. Eksioglu, Xianghong Chen, Joseph Johnson, Ling Zhang, Qing Zhang, Brittany Irvine, Thomas Cluzeau, David A. Sallman, Eric Padron, Rami S. Komrokji, Lubomir Sokol, Rebecca C. Coll, Avril A. B. Robertson, Matthew A. Cooper, John L. Cleveland, Luke O'neill, Sheng Wei, Alan F. List	2016	266
2	Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector Journal of Virology ·Hyun-Joo Nam, Michael Douglas Lane, Eric Padron, Brittney L. Gurda, Robert McKenna, Erik Kohlbrenner, George Aslanidi, Barry J. Byrne, Nicholas Muzyczka, Sergei Zolotukhin, Mavis Agbandje‐McKenna	2007	202
3	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study The Lancet Oncology ·Nancy Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao, Sean Yoder, Maria E. Balasis, Tania Mesa, David A. Sallman, Jeffrey E. Lancet, Rami S. Komrokji, Alan F. List, Howard L. McLeod, Melissa Alsina, Rachid Baz, Kenneth H. Shain, Dana E. Rollison, Eric Padron	2016	199
4	Structurally Mapping the Diverse Phenotype of Adeno-Associated Virus Serotype 4 Journal of Virology ·L. Govindasamy, Eric Padron, Robert McKenna, Nicholas Muzyczka, Nikola Kaludov, John A. Chiorini, Mavis Agbandje‐McKenna	2006	165
5	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes Leukemia ·Mrinal M. Patnaik, Eric Padron, Rebecca R. Laborde, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Janice M. Hodnefield, Ryan A. Knudson, Rhett P. Ketterling, Aref Al‐Kali, Animesh Pardanani, Najla Al Ali, R S Komroji, A Tefferi	2013	145
6	Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes Leukemia ·David A. Sallman, Rami S. Komrokji, Christine Vaupel, Thomas Cluzeau, Susan Geyer, Kathy L. McGraw, Najla H. Al Ali, Jeffrey E. Lancet, Matthew J. McGinniss, Shareef Nahas, Alexander Smith, Austin Kulasekararaj, G J Mufti, Alan F. List, Jeff Hall, Eric Padron	2015	137
7	GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia Blood ·Eric Padron, Jeffrey S. Painter, Sateesh Kunigal, Adam W. Mailloux, Kathy L. McGraw, Jessica M. McDaniel, Eun Hee Kim, Christopher Bebbington, Mark Baer, Geoffrey Yarranton, Jeffrey E. Lancet, Rami S. Komrokji, Omar Abdel‐Wahab, Alan F. List, Pearlie K. Epling‐Burnette	2013	108
8	Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation Annals of Hematology ·Andrew Kuykendall, Savan Shah, Chetasi Talati, Najla Al Ali, Kendra Sweet, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji	2017	94
9	Autoimmune diseases and myelodysplastic syndromes American Journal of Hematology ·Rami S. Komrokji, Austin Kulasekararaj, Najla H. Al Ali, Shahram Kordasti, Emily Bart‐Smith, Benjamin M. Craig, Eric Padron, Ling Zhang, Jeffrey E. Lancet, Javier Pinilla‐Ibarz, Alan F. List, Ghulam J. Mufti, Pearlie K. Epling‐Burnette	2016	89
10	Structure of Adeno-Associated Virus Type 4 Journal of Virology ·Eric Padron, Valorie D. Bowman, Nikola Kaludov, L. Govindasamy, Hazel C. Levy, Phillip Nick, Robert McKenna, Nicholas Muzyczka, John A. Chiorini, Timothy S. Baker, Mavis Agbandje‐McKenna	2005	82
11	Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium Cancer ·Elias Jabbour, Guillermo Garcia‐Manero, Paolo Strati, Asmita Mishra, Najla H. Al Ali, Eric Padron, Jeffrey E. Lancet, Tapan M. Kadia, Naval Daver, Susan O’Brien, David P. Steensma, Mikkael A. Sekeres, Steven D. Gore, Amy E. DeZern, Gail J. Roboz, Alan F. List, Hagop M. Kantarjian, Rami S. Komrokji	2014	80
12	Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure Blood Advances ·Brian Ball, Christopher Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prébet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg	2020	78
13	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults HemaSphere ·Raphaël Itzykson, Pierre Fenaux, David Bowen, Nicholas C.P. Cross, Jörge E. Cortes, Théo de Witte, Ulrich Germing, Francesco Onida, Eric Padron, Uwe Platzbecker, Valeria Santini, Guillermo Sanz, Éric Solary, Arjan van de Loosdrecht, Luca Malcovati	2018	65
14	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients Leukemia ·Giacomo Coltro, Abhishek A. Mangaonkar, Terra L. Lasho, Christy M. Finke, Prateek Pophali, Ryan M. Carr, Naseema Gangat, Moritz Binder, Animesh Pardanani, Martín E. Fernández-Zapico, Keith D. Robertson, Alberto Bosi, Nathalie Droin, Alessandro M. Vannucchi, Ayalew Tefferi, Anthony M. Hunter, Eric Padron, Éric Solary, Mrinal M. Patnaik	2019	63
15	A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) Clinical Cancer Research ·Eric Padron, Amy E. DeZern, Marcio Andrade‐Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E. Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P. Steensma, Gail J. Roboz, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji	2016	62
16	Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes American Journal of Hematology ·Rami S. Komrokji, Maria Corrales‐Yepez, Mohamed A. Kharfan‐Dabaja, Najla H. Al Ali, Eric Padron, Dana E. Rollison, Javier Pinilla‐Ibarz, Ling Zhang, Pearlie K. Epling‐Burnette, Jeffrey E. Lancet, Alan F. List	2012	57
17	Managing Clonal Hematopoiesis in Patients With Solid Tumors Journal of Clinical Oncology ·Kelly L. Bolton, Nancy Gillis, Catherine C. Coombs, Koichi Takahashi, Ahmet Zehir, Rafael Bejar, Guillermo Garcia‐Manero, P. Andrew Futreal, Brian C. Jensen, Luis A. Díaz, Dipti Gupta, Simon Mantha, Virginia M. Klimek, Elli Papaemmanuil, Ross L. Levine, Eric Padron	2018	52
18	Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes Blood Advances ·Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman	2021	50
19	Key Lessons Learned from Moffitt’s Molecular Tumor Board: The Clinical Genomics Action Committee Experience The Oncologist ·Todd C. Knepper, Gillian C. Bell, J. Kevin Hicks, Eric Padron, Jamie K. Teer, Teresa T. Vo, Nancy Gillis, Neil Mason, (unknown), Christine M. Walko	2017	49
20	Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes American Journal of Hematology ·Asmita Mishra, Maria Corrales‐Yepez, Najla Al Ali, Mohamed A. Kharfan‐Dabaja, Eric Padron, Ling Zhang, Pearlie K. Epling‐Burnette, Javier Pinilla‐Ibarz, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji	2013	47

About Eric Padron

Eric Padron is a scholar working on Hematology, Genetics, Cancer Research, Emergency Medicine and Pathology and Forensic Medicine, having authored 331 papers that have together received 4.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (260 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (120 papers), Chronic Myeloid Leukemia Treatments (65 papers), Chronic Lymphocytic Leukemia Research (53 papers), Lymphoma Diagnosis and Treatment (25 papers), Cancer Genomics and Diagnostics (24 papers), Acute Lymphoblastic Leukemia research (22 papers) and Hematological disorders and diagnostics (18 papers). The work is most often cited by research in Hematology (2.8k citations), Genetics (1.7k citations), Molecular Biology (1.6k citations), Genetics (620 citations) and Immunology (464 citations). Eric Padron has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Rami S. Komrokji, Alan F. List, Jeffrey E. Lancet, David A. Sallman, Najla Al Ali, Najla H. Al Ali, Robert McKenna, Mavis Agbandje‐McKenna, Kendra Sweet and Nicholas Muzyczka. Their work appears in journals such as Blood, Leukemia Research, Leukemia, American Journal of Hematology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact